<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370979</url>
  </required_header>
  <id_info>
    <org_study_id>5973</org_study_id>
    <nct_id>NCT02370979</nct_id>
  </id_info>
  <brief_title>Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients</brief_title>
  <acronym>DRONE</acronym>
  <official_title>Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center prospective study. The primary objective of DRONE study is to
      investigate the change of the size of HIV-1 DNA reservoir in blood from baseline to week 48
      (W48) in participants treated by DTG-based regimen. Secondary objectives include: DTG
      pharmacokinetic and analysis of biomarkers of immune activation from baseline to W48.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Proviral HIV-1 DNA at Week 48</measure>
    <time_frame>baseline (Day 0) and Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dolutegravir pharmacokinetic (dolutegravir pharmacological blood levels)</measure>
    <time_frame>Week 4, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of biomarkers of immune activation</measure>
    <time_frame>baseline (Day 0), Week 24 and Week 48</time_frame>
    <description>CRPus, IL-6, neopterin, D-dimer, CD14s</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <arm_group_label>Dolutegravir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged from de 18 to 80 years

          -  Patient starting a DTG-regimen

          -  Patients agreeing to use methods of birthcontrol while on the study and during the 6
             weeks after stopping DTG treatment

          -  Signed and dated written informed consent is obtained from the subject or the
             subject's legal representative prior to screening

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  HBV or HCV coinfection

          -  Participation in another clinical drug or device trial where the last dose of drug was
             within the past 30 days or an investigational medical device is currently implanted

          -  An active AIDS-defining condition at Screening

          -  Documented resistance to DTG

          -  Allergy or intolerance to the study drugs or their components or drugs of their class

          -  Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4
             lipids) at Screening.

          -  Coadministration with Dofelitide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David REY, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samira FAFI-KREMER, PhD</last_name>
    <phone>+33369551438</phone>
    <email>samira.fafi-kremer@unistra.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier de Belfort-Montbéliard</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin MARTINOT, MD</last_name>
      <email>martin.martinot@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse Cedex</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geneviève BECK WIRTH, MD</last_name>
      <email>beck-wirthg@ch-mulhouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David REY, PhD</last_name>
      <email>david.rey@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>August 6, 2015</last_update_submitted>
  <last_update_submitted_qc>August 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dolutegravir</keyword>
  <keyword>Proviral HIV-1 DNA</keyword>
  <keyword>Reservoir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

